BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30

• 

  Kenny Walter

  Kenny Walter is a freelance medical news writer based in Lavallette, NJ. He can be reached at kenneth.walter@gmail.com and on LinkedIn.
  
  
• Foresight Diagnostics

  Foresight Diagnostics is a precision medicine company developing a novel liquid biopsy test for the measurement of minimal residual disease (MRD) for aid in patient management that is funded by leading diagnostics VC firms in Silicon Valley.
• 

  Legal

  Sanofi Sues Sarepta Over Elevidys DMD Gene Therapy, Alleges Patent Infringement

  Sarepta has been hit with another patent infringement lawsuit, this time from Sanofi and its subsidiary Genzyme alleging that the biotech used protected technology related to AAV vectors.

  August 1, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Job Trends

  California’s Jobs Outlook: Life Sciences Sector Inching Toward Recovery?

  While many describe California as having a tough life sciences market, there’s some optimism that employment opportunities will improve soon, according to California Life Sciences President and CEO Mike Guerra.

  August 1, 2024

   · 

  5 min read

   · 

  Angela Gabriel
• 

  Cardiovascular disease

  Lilly’s Tirzepatide Clears Phase III Cardiovascular Study on Heels of Novo

  Eli Lilly on Thursday released late-stage data showing a 38% reduction in the risk of heart failure outcomes, as it plays catch-up with Novo Nordisk’s semaglutide which won the FDA’s cardio nod in March.

  August 1, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Deals

  Otsuka Pays Up to $1.1B to Buy Jnana, Adds Drug Discovery Capabilities

  With an upfront $800 million payment and $325 million in potential milestones, Otsuka Pharmaceutical is acquiring Jnana Therapeutics’ drug discovery platform and rare disease candidate, the companies announced Thursday.

  August 1, 2024

   · 

  2 min read

   · 

  Nick Paul Taylor
• 

  IRA

  Novo Loses IRA Case as NJ Judge Asserts Price Negotiations Are Voluntary

  Reiterating his ruling in a prior Inflation Reduction Act case, New Jersey District Court Judge Zahid Quraishi ruled that Novo Nordisk’s participation in the Medicare Drug Price Negotiation Program is of its own free will.

  August 1, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Adcomms

  FDA Questions Strength of Evidence Backing Zevra’s Rare Disease Therapy Ahead of Adcomm

  The Genetic Metabolic Diseases Advisory Committee will meet on Friday to discuss Zevra’s modified scale to describe the efficacy of its drug candidate for the treatment of Niemann-Pick disease type C.

  August 1, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Earnings

  Moderna Cuts Full-Year Revenue Guidance as COVID-19 Vaccine Sales Crater in Q2

  Moderna’s stock price plunged more than 20% in Thursday morning trading after the company lowered its 2024 revenue guidance due to weak demand for its coronavirus vaccine in the second quarter.

  August 1, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Drug Development

  The Political Shape of the Future Clinical Trial Space

  In this episode, Lori and guests discuss the pursuit of adequate representation and how clinical trials are being shaped by the legal environment they operate within.

  August 1, 2024

   · 

  1 min read

   · 

  Lori Ellis